Directorate Change

Evgen Pharma plc

 ("Evgen Pharma" or the "Company")

Directorate Change

Evgen Pharma plc (AIM: EVG), the clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces the resignation with immediate effect of Dr. Stephen Franklin as Chief Executive Officer of the Company. Having led Evgen for over 12 years Steve has, with the support of the Board, decided to pursue other opportunities.

Barry Clare will become Executive Chairman on a temporary basis until a new CEO is appointed with the appropriate experience to take Evgen through the next exciting stages of its development. Barry, together with our strong group of Non-Executive Directors; Susan Clement-Davies, Sue Foden and Alan Barge, will support the executive team on business development and pre-clinical and clinical projects. The Company remains committed to developing sulforaphane-based medicines for the treatment of breast cancer and multiple other diseases and continues to collaborate with its various hospital and university partners.

The search for a replacement to fill the role is underway and the Company will update the market in due course.

Barry Clare, Non-Executive Chairman, said: "On behalf of the Board, I would like to extend our sincere gratitude to Steve for all his efforts and his guidance since Evgen's inception. His contribution to the Company over the years has been invaluable and we would like to offer our huge thanks for all his support and hard work. We wish him all the best in his future endeavours."

The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014.

Enquiries:

About Evgen Pharma plc 

Evgen Pharma is a clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases. The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.

Clinical data from the Company's open-label Phase II STEM trial has shown that SFX-01 can halt the growth of progressing tumours in patients with oestrogen-positive (ER+) metastatic breast cancer, and in some cases significantly shrink the tumour, whilst causing very few side effects.

The Company commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG.  

For further information, please visit: www.evgen.com